Resolving disease
Promoting host defense
Pioneering Resolution Therapy
Thetis is a clinical-stage pharmaceutical company developing oral TP-317 for inflammatory bowel disease (IBD) and cancer ─ without immunosuppression.
TP-317 is a Resolvin E1 (RvE1) drug that activates BLT1 — expressed on epithelial and immune cells — to promote tissue and immune homeostasis.
In a Phase 1a healthy-volunteer study, oral TP-317 was well-tolerated and demonstrated BLT1 target engagement.
A 12-week study in moderate-to-severe ulcerative colitis patients is scheduled to begin in 2026.